Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 3, 1999, Pages 552-561

  Niemeier, Andreas ^a   Willnow, Thomas ^b   Dieplinger, Hans ^c   Jacobsen, Christian ^d   Meyer, Nicolette ^a   Hilpert, Jan ^b   Beisiegel, Ulrike ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

Glycoprotein 330; LDL; LDLR gene family; Lipoprotein(a); Megalin

Indexed keywords

1,1' DIOCTADECYL 3,3,3',3' TETRAMETHYLINDOCARBOCYANINE; CALCIUM; FLUORESCENT DYE; IODINE 125; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MEGALIN; RECEPTOR PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL LINE; CONTROLLED STUDY; EMBRYO; IN VITRO STUDY; KNOCKOUT GENE; LIGAND BINDING; LIPOPROTEIN METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; YOLK SAC;

EID: 0032975165     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.3.552     Document Type: Article

References (63)

1. Utermann G. Lipoprotein(a). In: Scriver CR, Beaudel AL, Sly WS, eds. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill Inc; 1993.
2. Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H. Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci. 1996;33:495-543.
3. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.
4. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. [published erratum appears in J Clin Invest. 1991;88:723]. J Clin Invest. 1991;87:2153-2161.
5. Kraft HG, Kochl S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum Genet. 1992;90:220-230.
6. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo BG, Qunici GB. Lipoprotein Lp(a), and the risk for myocardial infarction. Atherosclerosis. 1981;38:51-61.
7. Scanu AM. Lipoprotein(a): a potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med. 1988;112: 1045-1047.
8. Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest. 1992;89:1040-1046.
9. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol. 1992;69:1251-1254.
10. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. (published erratum appears in Arteriosclerosis. 1990;10:1147). Arteriosclerosis. 1989;9:579-592.
11. Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, Graf H, Konig P. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest. 1993;91:397-401.
12. Kronenberg F, Konig P, Lhotta K, Ofner D, Sandholzer C, Margreiter R, Dosch E, Utermann G, Dieplinger H. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb. 1994;14:1399-1404.
13. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis. 1996;27:1-25.
14. Kronenberg F, Trenkwalder E, Lingenhel A, Friedrich G, Lhotta K, Schober M, Moes N, Konig P, Utermann G, Dieplinger H. Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res. 1997;38:1755-1763.
15. Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest. 1996;98:2414-2424.
16. Mooser V, Seabra MC, Abedin M, Landschulz KT, Marcovina S, Hobbs HH. Apolipoprotein(a) kringle 4-containing fragments in human urine: relationship to plasma levels of lipoprotein(a). J Clin Invest. 1996;97: 858-864.
17. Kostner KM, Maurer G, Huber K, Stefenelli T, Dieplinger H, Steyrer E, Kostner GM. Urinary excretion of apo(a) fragments: role in apo(a) catabolism. Arterioscler Thromb Vasc Biol. 1996;16:905-911.
18. Maartmann MK, Berg K. Lp(a) lipoprotein enters cultured fibroblasts independently of the plasma membrane low density lipoprotein receptor. Clin Genet. 1981;20:352-362.
19. Havekes L, Vermeer BJ, Brugman T, Emeis J. Binding of LP(a) to the low density lipoprotein receptor of human fibroblasts. FEBS Lett. 1981; 132:169-173.
20. Krempler F, Kostner GM, Roscher A, Haslauer F, Bolzano K, Sandhofer F. Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man. J Clin Invest. 1983;71:1431-1441.
21. Widhalm K, Genser D. Increased lipoprotein(a) levels in children with familial hypercholesterolaemia. [letter]. Lancet. 1988;2:1262.
22. Hofmann SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Hammer RE. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest. 1990;85:1542-1547.
23. Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E. Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci U S A. 1989;86:4171-4174.
24. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246: 904-910.
25. Reblin T, Niemeier A, Meyer N, Willnow TE, Kronenberg F, Dieplinger H, Greten H, Beisiegel U. Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein. J Lipid Res. 1997;38:2103-2110.
26. Argraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest. 1997;100:2170-2181.
27. Kerjaschki D, Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A. 1982;79:5557-5581.
28. Kerjaschki D, Ullrich R. Diem K, Pietromonaco S, Orlando RA, Farquhar MG. Identification of a pathogenic epitope involved in initiation of Heymann nephritis. Proc Natl Acad Sci U S A. 1992;89:11179-11183.
29. Raychowdhury R, Niles JL, McCluskey RT, Smith JA. Autoimmune target in Heymann nephritis is a glycoprotein with homology to the LDL receptor. Science. 1989;244:1163-1165.
30. Chen WJ, Goldstein JL, Brown MS. NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor. J Biol Chem. 1990;265:3116-3123.
31. Saito A, Pietromonaco S, Loo AK, Farquhar MG. Complete cloning and sequencing of rat gp330/"megalin," a distinctive member of the low density lipoprotein receptor gene family. Proc Natl Acad Sci U S A. 1994;91:9725-9729.
32. 2+)-binding receptor with potential intracellular signaling properties. Eur J Biochem. 1996;239:132-137.
33. Kanalas JJ, Makker SP. Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen. J Biol Chem. 1991;266:10825-10829.
34. Christensen EI, Gliemann J, Moestrup SK. Renal tubule gp330 is a calcium binding receptor for endocytic uptake of protein. J Histochem Cytochem. 1992;40:1481-1490.
35. Kounnas MZ, Argraves WS, Strickland DK. The 39-kDa receptor-associated protein interacts with two members of the low density lipoprotein receptor family, α2-macroglobulin receptor and glycoprotein 330. J Biol Chem. 1992;267:21162-21166.
36. Willnow TE, Goldstein JL, Orth K, Brown MS, Herz J. Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J Biol Chem. 1992;267: 26172-26180.
37. Kounnas MZ, Chappell DA, Strickland DK, Argraves WS. Glycoprotein 330, a member of the low density lipoprotein receptor family, binds lipoprotein lipase in vitro. J Biol Chem. 1993;268:14176-14181.
38. Moestrup SK, Nielsen S, Andreasen P, Jorgensen KE, Nykjaer A, Roigaard H, Gliemann J, Christensen EI. Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. J Biol Chem. 1993;268:16564-16570.
39. Kounnas MZ, Loukinova EB, Stefansson S, Harmony JA, Brewer BH, Strickland DK, Argraves WS. Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. [published erratum appears in J Biol Chem. 1995;270:23234]. J Biol Chem. 1995;270: 13070-13075.
40. Moestrup SK, Cui S, Vorum H, Bregengard C, Bjorn SE, Norris K, Gliemann J, Christensen EI. Evidence that epithelial glycoprotein 330/ megalin mediates uptake of polybasic drugs, [see comments]. J Clin Invest. 1995;96:1404-1413.
41. Stefansson S, Chappell DA, Argraves KM, Strickland DK, Argraves WS. Glycoprotein 330/low density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins via interaction with apolipoprotein B100. J Biol Chem. 1995;270:19417-19421.
42. Cui S, Verroust PJ, Moestrup SK, Christensen EI. Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am J Physiol. 1996;271:F900-F907.
43. Moestrup SK, Birn H, Fischer PB, Petersen CM, Verroust PJ, Sim RB, Christensen EI, Nexo E. Megalin-mediated endocytosis of transcobalamin-vitamin-B12 complexes suggests a role of the receptor in vitamin-B12 homeostasis. Proc Natl Acad Sci U S A. 1996;93: 8612-8617.
44. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid-β at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A. 1996;93: 4229-4234.
45. Biemesderfer D, Dekan G, Aronson PS, Farquhar MG. Biosynthesis of the gp330/44-kDa Heymann nephritis antigenic complex: assembly takes place in the ER. Am J Physiol. 1993;264:F1011-F1020.
46. Zheng G, Bachinsky DR, Stamenkovic I, Strickland DK, Brown D, Andres G, McCluskey RT. Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/α2 MR, and the receptor-associated protein (RAP). J Histochem Cytochem. 1994; 42:531-542.
47. Willnow TE, Rohlmann A, Horton J, Otani H, Braun JR, Hammer RE, Herz J. RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors. EMBO J. 1996;15:2632-2639.
48. Medh JD, Fry GL, Bowen SL, Pladet MW, Strickland DK, Chappell DA. The 39-kDa receptor-associated protein modulates lipoprotein catabolism by binding to LDL receptors. J Biol Chem. 1995;270:536-540.
49. Kounnas MZ, Haudenschild CC, Strickland DK, Argraves WS. Immunological localization of glycoprotein 330, low density lipoprotein receptor related protein and 39 kDa receptor associated protein in embryonic mouse tissues. In Vivo. 1994;8:343-351.
50. 2+)-sensing protein. J Histochem Cytochem. 1997;45: 383-392.
51. Willnow TE, Hilpert J, Armstrong SA, Rohlmann A, Hammer RE, Burns DK, Herz J. Defective forebrain development in mice lacking gp330/ megalin. Proc Natl Acad Sci U S A. 1996;93:8460-8464.
52. Willnow TE, Herz J. Genetic deficiency in low density lipoprotein receptor-related protein confers cellular resistance to Pseudomonas exotoxin A: evidence that this protein is required for uptake and degradation of multiple ligands. J Cell Sci. 1994;107:719-726.
53. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;195:265-275.
54. Neville DMJ. Molecular weight determination of protein-dodecyl sulfate complexes by gel electrophoresis in a discontinuous buffer system. J Biol Chem. 1971;246:6328-6334.
55. Sambrook J, Fritsch EF, Marcovina S. Molecular Cloning: A Laboratory Manual. New York, NY: Cold Spring Harbor Laboratory Press; 1989.
56. Dieplinger H, Gruber G, Krasznai K, Reschauer S, Seidel C, Burns G, Muller HJ, Csaszar A, Vogel W, Robenek H, et al. Kringle 4 of human apolipoprotein[a] shares a linear antigenic site with human catalase. J Lipid Res. 1995;36:813-822.
57. McFarlane AS. Efficient trace labeling of proteins with iodine. Nature. 1958;182:53.
58. Orth K, Madison EL, Gething MJ, Sambrook JF, Herz J. Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/α2-macroglobulin receptor. Proc Natl Acad Sci U S A. 1992;89:7422-7426.
59. Fraker PJ, Speck-JC J. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3α,6α-diphrenylglycoluril. Biochem Biophys Res Commun. 1978;80:849-857.
60. Goldstein JL, Basu SK, Brown MS. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 1983;98: 241-260.
61. Pitas RE, Innerarity TL, Weinstein JN, Mahley RW. Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy. Arteriosclerosis. 1981;1:177-185.
62. Armstrong VW, Walli AK, Seidel D. Isolation, characterization, and uptake in human fibroblasts of an apo (a)-free lipoprotein obtained on reduction of lipoprotein(a). J Lipid Res. 1985;26:1314-1323.
63. Snyder ML, Hay RV, Whitington PF, Scanu AM, Fless GM. Binding and degradation of lipoprotein(a) and LDL by primary cultures of human hepatocytes: comparison with cultured human monocyte-macrophages and fibroblasts. Arterioscler Thromb. 1994;14:770-779.